DDInter1055 DDInter1228
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. Mipomersen is indicated in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications. It is marketed under the brand name Kynamro in the United States, and the FDA label includes a black box warning of hepatoxicity. Specifically, elevations in the liver enzymes, i.e. transaminases, and in liver fat (hepatic steatosis) have been reported. Due to this serious risk of liver toxicity, mipomersen sodium is only available to patients under the restricted program called Kynamro Risk Evaluation and Mitigation Strategy program.
Levofloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Regorafenib
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Levofloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Diclofenac
Diclofenac {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Levofloxacin {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Myocardial infarction {u} (Side Effect) is caused by {v} (Compound) Regorafenib
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Levofloxacin {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Myocardial infarction {u} (Side Effect) is caused by {v} (Compound) Diclofenac
Diclofenac {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Levofloxacin {u} (Compound) upregulates {v} (Gene) GPATCH8
GPATCH8 {u} (Gene) is upregulated by {v} (Compound) Stanozolol
Stanozolol {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Levofloxacin {u} (Compound) upregulates {v} (Gene) GPATCH8
GPATCH8 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diclofenac
Diclofenac {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Levofloxacin {u} (Compound) resembles {v} (Compound) Moxifloxacin
Moxifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diclofenac
Diclofenac {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may lead to a major life threatening interaction when taken with {v} Pazopanib
Pazopanib {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Levofloxacin {u} (Compound) resembles {v} (Compound) Lomefloxacin
Lomefloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diclofenac
Diclofenac {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Levofloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Regorafenib (Compound) and Regorafenib may lead to a major life threatening interaction when taken with Mipomersen
Levofloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Diclofenac (Compound) and Diclofenac may lead to a major life threatening interaction when taken with Mipomersen
Levofloxacin (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Regorafenib (Compound) and Regorafenib may lead to a major life threatening interaction when taken with Mipomersen
Levofloxacin (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Diclofenac (Compound) and Diclofenac may lead to a major life threatening interaction when taken with Mipomersen
Levofloxacin (Compound) upregulates GPATCH8 (Gene) and GPATCH8 (Gene) is upregulated by Stanozolol (Compound) and Stanozolol may lead to a major life threatening interaction when taken with Mipomersen
Levofloxacin (Compound) upregulates GPATCH8 (Gene) and GPATCH8 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may lead to a major life threatening interaction when taken with Mipomersen
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Mipomersen
Levofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Mipomersen
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Mipomersen
Levofloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Mipomersen